Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.41 |
| ▸ | MLNR | O43193 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058871 | 1.00 | SIGMAR1 (0.56) | SIGMAR1GRM2MLNRMAPTALDH1A1 | |
| SCHEMBL14401346 | 1.00 | SIGMAR1 (0.56) | SIGMAR1GRM2MLNRMAPTALDH1A1 | |
| SCHEMBL3176427 | 1.00 | SIGMAR1 (0.56) | SIGMAR1GRM2MLNRMAPTALDH1A1 | |
| SCHEMBL3165725 | 1.00 | SIGMAR1 (0.56) | SIGMAR1GRM2MLNRMAPTALDH1A1 | |
| SCHEMBL5060895 | 1.00 | SIGMAR1 (0.56) | SIGMAR1GRM2MLNRMAPTALDH1A1 | |
| SCHEMBL10504025 | 0.86 | SIGMAR1 (0.51) | SIGMAR1GRM2MAPTALDH1A1 | |
| SCHEMBL14188698 | 0.86 | SIGMAR1 (0.51) | SIGMAR1MAPTALDH1A1 | |
| SCHEMBL5816124 | 0.85 | SIGMAR1 (0.62) | SIGMAR1MAPTALDH1A1 | |
| SCHEMBL15292046 | 0.84 | SIGMAR1 (0.50) | SIGMAR1MAPTALDH1A1 | |
| SCHEMBL3401749 | 0.84 | ALDH1A1 (0.51) | SIGMAR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | claimed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | claimed |
| US-7488744-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080119485-A1 | Novel Benzofurans and Indols | ACTIVE BIOTECH AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7339059-B2 | Benzofurans and indols | ACTIVE BIOTECH AB (SE) | 2008-03-04 | — | — | US | disclosed |
| EP-1196404-B1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-7304048-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7291613-B2 | Inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1178983-B1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2007-10-24 | — | — | EP | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002042292-A2 | INDOL DERIVATIVE AND THEIR USE AS INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| EP-1196404-A1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca UK Limited (GB) | 2002-04-17 | — | — | EP | disclosed |
| EP-1178983-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | Scios Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| WO-2001002381-A1 | PIPERAZINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000071535-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0988292-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056771-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119485-A1 | Novel Benzofurans and Indols | FOXM1, IKZF3, BRPF3 | SIGMAR1 288/4885GRM2 3855/4885MLNR 2401/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | SIGMAR1 1023/4885GRM2 2900/4885MLNR 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.